DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare ...
Revision of DaVita to Hold, as incremental capital investments have failed to create market value, signaling subpar returns and economic value destruction. Despite strong cash flow and margin ...
We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where DaVita Inc. (NYSE:DVA) stands against other small-cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback